Last update: Sept. 12, 2019


Low Risk for breastfeeding

Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Fully human IgG2 monoclonal antibody produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells.
Indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.
Administration by subcutaneous injection once a month.

Since the last update we have not found any published data on its excretion in breast milk.

Its very high molecular weight makes transfer into breastmilk in significant quantities very unlikely
Due to its protein nature, it is inactivated in the gastrointestinal tract, and is not absorbed, (it has virtually no oral bioavailability), which hinders or prevents its transfer from breastmilk to infant except in premature babies and the immediate neonatal period, when there may be greater intestinal permeability.

A 22-month-old infant whose mother was taking eremumab had no adverse effects; he had no infections or developmental problems (Henze 2019).


Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

依瑞奈人单抗 is Erenumab in Chinese.

Is written in other languages:


依瑞奈人单抗 belongs to this group or family:


Main tradenames from several countries containing 依瑞奈人单抗 in its composition:


Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 146.000 daltons
VD 0.06 l/Kg
Tmax 96 - 144 hours
T1/2 672 hours


  1. Henze T. Erenumab During Breastfeeding. Breastfeed Med. 2019 Aug 5. Abstract
  2. EMA-Novartis. Erenumab (Aimovig). Ficha técnica. 2018 Full text (in our servers)
  3. EMA-Novartis. Erenumab (Aimovig). Drug Summary. 2018 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM